Omeros Corporation
HealthcareNASDAQ:OMER · NASDAQ Global Market
-$1.45 today
Vol 7.77M · Avg 1.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.8%
avg 244.0%
ROIC
-45.3%
avg -86.6%
ROA
-1.0%
avg -61.4%
Analysis
ROE is currently the strongest return metric at 2.8% versus its period average of 244.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gregory A. Demopulos | Co-Founder, Chairman, Chief Executive Officer & President | $1.97M | — | 67 | $1.83M | 2.52% |
Peter Cancelmo | Vice President, General Counsel & Corporate Secretary | $665,445.00 | — | 47 | $100,000.00 | 0.14% |
David J. Borges | Vice President of Finance, Chief Accounting Officer & Treasurer | $443,780.00 | — | 61 | $35,067.00 | 0.05% |
Andreas Grauer | Vice President & Chief Medical Officer | — | — | 65 | — | — |
Catherine A. Melfi | Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems | — | — | 67 | — | — |
George A. Gaitanaris | Chief Scientific Officer & Vice President of Science | — | — | 69 | — | — |
Peter W. Williams | Vice President of Human Resources | — | — | 58 | $100,000.00 | 0.14% |
Nadia Dac | Vice President & Chief Commercial Officer | — | — | 56 | — | — |
Pamela Pierce Palmer | Co-Founder | — | — | 63 | — | — |
David W. Ghesquiere | Vice President & Chief Business Development Officer | — | — | 59 | $65,000.00 | 0.09% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$837,954.00
Net Sentiment
$837,954.00
Net selling
Most Active
Borges David J.
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $837,954.00 over the last 12 months. That adds up to net selling of $837,954.00. Borges David J. was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +30.9% | +27.3% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +30.9% over three years. Forward estimates point to Revenue at +27.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages OMER?
Omeros Corporation (OMER) lists 10 active executives. The top listed executive is Andreas Grauer, Vice President & Chief Medical Officer.
Are OMER insiders buying or selling?
Recent insider activity shows net buying of $30.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.